Question

I am a breastfeeding mother and i want to know if it is safe to use MS-325? Is MS-325 safe for nursing mother and child? Does MS-325 extracts into breast milk? Does MS-325 has any long term or short term side effects on infants? Can MS-325 influence milk supply or can MS-325 decrease milk supply in lactating mothers?

MS-325 lactation summary

MS-325 usage has low risk in breastfeeding
  • DrLact safety Score for MS-325 is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of MS-325 may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that MS-325 may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of MS-325 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using MS-325 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About MS-325 usage in lactation

Quelato de gadolinio con acción y usos similares a los del ácido gadopentetico pero de más larga vida media.A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.Durante la lactancia puede ser preferible elegir un contraste de gadolinio de eliminación más rápida, especialmente durante el periodo neonatal. Los diversos medios de contraste derivados del gadolinio para exploraciones de Resonancia Magnética Nuclear (RMN) se consideran compatibles con la lactancia por eliminarse rápidamente (semivida de eliminación menor de 2 horas) sin apenas metabolización y ser prácticamente inabsorbibles por vía oral. Son muy similares estructuralmente unos a otros y de alguno de ellos hay datos de su nula o mínima excreción en leche. Menos del 0,04% de la dosis administrada a la madre acaba pasando a la leche. Debido a su escasa biodisponibilidad oral, la absorción intestinal es menor del 1% de la dosis que haya podido tomar el lactante. La dosis máxima que recibe el lactante es menor del 0,0004% de la dosis materna, lo que supone mucho menos de la dosis que se administra a un lactante o recién nacido al que se le practica una RMN. La mayor parte de sociedades científicas de radiología están de acuerdo en que tras una exploración de RMN no es preciso esperar ningún tiempo para amamantar. Algunos autores y sociedades recomiendan evitar en las mujeres lactantes, especialmente en el periodo neonatal, los contrastes de gadolinio de alto riesgo de fibrosis sistémica nefrogénica: gadoversetamida, gadodiamida y gadopentato, eligiendo los de bajo riesgo: gadoterato, gadoteridol y gadobutrol.

Answer by DrLact: About MS-325 usage in lactation

There is no published experience with MS-325 during breastfeeding. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1][2][3] However, because there is no published experience with MS-325 during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.